Targeting specific PAD isozymes for different cancer types and subtypes is an active area of research, focusing on the relative significance of the three main isozymes (PAD2, PAD3, and PAD4) in malignancies (Arisan et al., 2020). This evidence concerns the gene PADI2 and cancer.